Secondary Site Ligand for Integrin α V β 3 Enables Targeted mRNA Delivery
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.1554405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Sebastian Bayer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Integrin alphaVbeta3, RNA, Messenger. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBR Global Scholars Program.
Abstract (Originalsprache)
Poor perfusion and abnormal vasculature constrain direct drug delivery to solid tumors. Hence, targeting neighboring tumor endothelial cells via the upregulated marker integrin α V β 3 is a promising strategy. Orthosteric arginine–glycine–aspartate (RGD) ligands of α V β 3 achieve high affinities but suffer from cross‐reactivity. Alternatively, selective targeting of α V β 3 could potentially be achieved via low‐affinity ligands, displayed multivalently on nanoparticles to leverage avidity. To avoid orthosteric site competition, we performed a fragment screening under RGD saturation. Structure–activity relationship (SAR) analysis of the initial hit revealed its binding motif, a 4‐methylpyrimidine‐2‐amine core and a conjugation‐tolerant position for linker attachment. Multivalent display of the lead compound on liposomes and lipid nanoparticles (LNPs) led to time‐, dose‐, and valency‐dependent uptake in α V β 3‐expressing model cells and in primary human umbilical vein endothelial cells (pHUVECs). In contrast to RGD‐decorated NPs, fragment‐targeted NPs show superselective behavior ( α κ ≈3), that is, a sharp valency‐dependent threshold, enabling selective targeting of cells overexpressing α V β 3. Crucially, mRNA delivered by targeted LNPs translated into functional protein expression six‐fold over control. To our knowledge, these findings present the first non‐orthosteric, exogenous small‐molecule ligands for α V β 3 and outline their application as a multivalent, superselective delivery platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
- Vienna Doctoral School of Pharmaceutical, Nutritional and Sport Sciences, University of Vienna, Austria.
- Department of Microbiology, Immunology and Genetics, Max F. Perutz Labs, Vienna, Austria.
ORCID-Profile: Sebastian Bayer, María García-García, Raffaele Senatore, Maria Stratoudaki, Alina Markhof, Anna Sophia Parianou, Christoph Rademacher
Förderung
- NIBR Global Scholars Program
Zitieren
APA
Bayer, S., García-García, M., Senatore, R., Stratoudaki, M., Markhof, A., Berger-Becvar, A., Parianou, A. S., & Rademacher, C. (2026). Secondary Site Ligand for Integrin α V β 3 Enables Targeted mRNA Delivery. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.1554405
Vancouver
Bayer S, García-García M, Senatore R, Stratoudaki M, Markhof A, Berger-Becvar A, et al. Secondary Site Ligand for Integrin α V β 3 Enables Targeted mRNA Delivery. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.1554405
BibTeX
@article{Bayer2026,
author = {Bayer, Sebastian and García-García, María and Senatore, Raffaele and Stratoudaki, Maria and Markhof, Alina and Berger-Becvar, Angelika and Parianou, Anna Sophia and Rademacher, Christoph},
title = {Secondary Site Ligand for Integrin α V β 3 Enables Targeted mRNA Delivery},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.1554405}
}
EUVIMED